Skip to main content

Medical Marijuana, Inc. Subsidiary Kannaway® Signs Trademark License and Royalty Agreement with Direct Selling Pet Food Company, Onboards Company’s Brand Ambassadors

SAN DIEGO, CA, Sept. 09, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has signed a Trademark License and Royalty Agreement with direct selling company The Best Friend (“TBF”). As a part of the agreement, the new venture, TBF by Kannaway®, will sell a super-premium line of veterinarian-developed pet food products, as well as a line of cannabidiol (CBD) tinctures designed for pets, throughout Europe.These pet food products are created by a research and development team composed of world-renowned premium dog breeders, scientists and veterinarians. They have been designed to meet the strictest requirements for quality, nutritional value, consistency, digestibility, and have a low risk of allergy reactions. The new line of TBF best-selling super-premium feeds includes:• Beef & Rice 3kg• Lamb & Rice 3kg• Junior Complex 3kg“CBD hemp oil has been researched by top veterinarians to improve cardiovascular, orthopedic and mental animal health,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We’re excited to be able to offer some of the highest-quality pet food products in Europe and soon launch a new line of CBD products that can nicely supplement them.” Brand ambassadors who were previously selling TBF products exclusively will now market and sell The Best Friend by Kannaway® as well as other CBD products through Kannaway®’s expansive direct selling network. “According to Grandview Research, Europe’s market for pet food in 2018 was the largest pet food market in the world and that growth only continues with a global pet food market that is expected to reach $113.08 billion by 2025,” said Kannaway® CEO Blake Schroeder. “Joining forces with TBF will not only allow us to expand our product offering and gain an entirely new subset of customers, but it will also allow TBF distributors to earn another source of revenue.”TBF was founded just 13 months ago by Tobias Sukenik, Michal Kyselica and Michal Prazenica, and has already achieved tremendous growth. Currently, TBF has over 10,000 registered partners in 6 countries, making it one of the fastest-growing pet direct selling companies in Europe. To learn more about The Best Friend by Kannaway®, please visit http://www.kannaway.com and attend the upcoming Kannaway® Europe webinar on September 10. About Kannaway®Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.About Medical Marijuana, Inc.We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT:Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com 
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
AttachmentMJNA

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.